Fostamatinib Disodium (R935788)
C-935788-015
Phase 2 small_molecule terminated
Quick answer
Fostamatinib Disodium (R935788) for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RIGEL PHARMACEUTICALS INC
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated